Month: June 2021

Palatin Announces Positive End-of-Phase 2 Meeting with FDA on PL9643 for the Treatment of Dry Eye Disease

Palatin and FDA Reach Agreement on Path to NDA Submission, including Trial Design, Endpoints, Interim Assessment, and Patient Population On Track to Initiate Phase 3 Study Calendar Q4 2021 with Data Expected Calendar 2H 2022 Jun 29, 2021, 07:30 ET CRANBURY, N.J., June 29, 2021 /PRNewswire/ — Palatin Technologies, Inc. (“Palatin”) (NYSE American: PTN) a …

Palatin Announces Positive End-of-Phase 2 Meeting with FDA on PL9643 for the Treatment of Dry Eye Disease Read More »

Palatin Announces New Additions to Its Senior Leadership Team

Michael B. Raizman, M.D. – Chief Medical Officer James E. Hattersley – Senior Vice President, Business Development J. Don Wang, Ph.D. – Vice President, Product Development Jun 28, 2021, 07:30 ET CRANBURY, N.J., June 28, 2021 /PRNewswire/ — Palatin Technologies, Inc. (“Palatin”) (NYSE American: PTN) a biopharmaceutical company developing first-in-class medicines based on molecules that …

Palatin Announces New Additions to Its Senior Leadership Team Read More »

Palatin Announces Adjournment of Annual Meeting of Stockholders

– Limited to Proposal 3, Amendment to Certificate of Incorporation to Increase Authorized Common Stock – Proposals 1, 2, and 4 were approved at the Annual Meeting – Scheduled to Reconvene July 8, 2021, 9:00 a.m. Eastern Daylight Time Jun 10, 2021, 07:30 ET CRANBURY, N.J., June 10, 2021 /PRNewswire/ — Palatin Technologies, Inc. (“Palatin”) …

Palatin Announces Adjournment of Annual Meeting of Stockholders Read More »

Scroll to Top